Premier stock to be acquired by Patient Square Capital for $28.25 per share

Investing.comTuesday, September 23, 2025 at 1:49:12 PM
Premier stock to be acquired by Patient Square Capital for $28.25 per share
Patient Square Capital is set to acquire Premier stock at a price of $28.25 per share, marking a significant move in the investment landscape. This acquisition is important as it reflects confidence in Premier's potential and could lead to new opportunities for growth and innovation within the company.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Patient Square Capital to Buy Premier Inc. in $2.6 Billion Deal
PositiveFinancial Markets
In a significant move for the healthcare sector, Patient Square Capital has announced its intention to acquire Premier Inc. for $2.6 billion, offering $28.25 per share, which represents a 9.7% premium over the company's recent closing price. This acquisition is noteworthy as it highlights the growing interest in healthcare investments and could lead to enhanced services and innovations within Premier, benefiting both the company and its stakeholders.
Premier shares surge as Patient Square Capital announces $2.6 billion acquisition
PositiveFinancial Markets
Shares of Premier have surged following the announcement that Patient Square Capital will acquire the company for $2.6 billion. This acquisition is significant as it highlights the growing interest in the healthcare sector and the potential for increased investment in innovative healthcare solutions. Investors are optimistic about the future of Premier under new ownership, which could lead to enhanced growth opportunities and improved services.
Latest from Financial Markets
Russians ramp up spending on foreign holidays – data
PositiveFinancial Markets
Recent data shows that Russians are significantly increasing their spending on foreign holidays, with Türkiye emerging as the top travel destination. This trend highlights a growing interest in international travel among Russians, which could have positive implications for the tourism industry and local economies in popular destinations.
F.D.A.’s Approval of Drug for Autism Upends Review Process
PositiveFinancial Markets
The FDA's recent approval of a new drug for autism marks a significant shift in the review process for treatments targeting this condition. This decision not only opens doors for innovative therapies but also highlights the growing recognition of autism in the healthcare landscape. It matters because it could lead to improved quality of life for individuals with autism and their families, offering hope where there was previously limited options.
Drone Swarm Software Maker Auterion Raises $130 Million
PositiveFinancial Markets
Auterion, a defense tech startup, has successfully raised $130 million in a Series B funding round, signaling strong investor confidence in its innovative drone software. This funding will enable Auterion to expand its technology for drone warfare, which is increasingly relevant in modern defense strategies. CEO Lorenz Meier discussed the implications of this funding on Bloomberg Tech, highlighting the potential for enhanced capabilities in military operations. This development is significant as it reflects the growing importance of advanced technology in defense and security.
FAT Brands engages advisers amid restructuring talks with bondholders - WSJ
NeutralFinancial Markets
FAT Brands is currently in discussions with advisers as it navigates restructuring talks with its bondholders. This development is significant as it highlights the company's efforts to manage its financial obligations and stabilize its operations. The outcome of these talks could impact the future of the brand and its ability to continue expanding in the competitive food industry.
Trump Blasts UN Over Immigration, Climate
NegativeFinancial Markets
In a fiery address at the United Nations General Assembly, President Donald Trump criticized the UN for not supporting his diplomatic initiatives, dismissing climate change as a hoax and labeling uncontrolled migration as the foremost political issue today. This speech highlights Trump's ongoing tension with international bodies and his controversial stance on global issues, which could impact future diplomatic relations and global cooperation.
Trump links autism to Tylenol and vaccines, claims not backed by science
NegativeFinancial Markets
Former President Donald Trump has stirred controversy by linking autism to the use of Tylenol and vaccines, a claim that lacks scientific backing. This assertion raises concerns as it may contribute to misinformation about autism and vaccine safety, potentially influencing public perception and health decisions. It's crucial to rely on credible scientific research when discussing such sensitive topics.